Name: Singapore Healthcare & Hospital Market Study 2026–2031
Brand: eFinancialModels
SKU: 641063
Availability: InStock

Cover image for eFinancialModels report: Singapore Healthcare & Hospital Market Study 2026–2031, featuring a modern glass hospital building at dusk.

Financial Model, Health Care

Financial Modeling, Financial Planning, Free Financial Model Templates, Market Studies, PDF

The investable view of Singapore healthcare, built for your model

Singapore is one of Asia’s most concentrated, highest-quality, and most internationally connected healthcare markets — and one of the hardest to size, because three very different engines drive demand at once. This study separates them so you can model them correctly.

Total current health expenditure reached roughly S$36 billion in 2024 (about 5 to 6 percent of GDP) and is projected to climb toward US$44 billion by 2030 as Singapore becomes a super-aged society. A compact, premium private hospital sector — led by IHH’s Parkway network and Raffles Medical — anchors domestic self-pay and a fast-growing medical-tourism export channel that treated 646,000 international patients in 2024. Behind it sits a world-scale biomedical manufacturing and research hub generating S$40 to 44 billion of output. This study shows how the three connect.

What you get

A 30-page Word and PDF study covering market size, supply, demand, pricing, scenarios, technology, regulation, competition, and recommendations.
12 EFM-branded charts — health expenditure, bed-capacity pipeline, operator footprint, medical-tourism patients and revenue, source-country mix, biomedical output, ageing, chronic-disease burden, funding-channel mix, and a three-scenario 2031 outlook.
A quantified Bear / Base / Bull scenario framework (probabilities 25 / 55 / 20) with a ready-to-use assumptions appendix and sensitivity table.
A source-verification workbook documenting every figure, with headline-number reconciliation and a competitive-coverage map.

Key findings

A dominant public system (over 12,000 acute beds across SingHealth, NHG Health, and NUHS) frames a premium private niche of roughly 1,500 to 1,800 private acute beds — small by capacity, outsized by revenue and brand.
Three demand engines move on three cycles: an acyclical ageing-and-chronic-disease baseline, a pro-cyclical medical-tourism export channel concentrated in Indonesia, and high-acuity spillover from the biomedical hub.
Medical tourism’s direct treatment revenue is estimated at roughly US$270 to 300 million (up to about US$0.7 billion on a broad economic basis) — and concentration in one source market is the channel’s defining risk.
The public bed pipeline adds about 13,600 system beds by 2030, both relieving and competing with private capacity.
Our Base Case sees private acute hospital revenue rising from about S$5.0 billion in 2024 to roughly S$8.3 billion by 2031.

Who it’s for

Financial modelers and advisors building hospital, clinic, medical-tourism, or biomedical-facility models; healthcare investors and operators evaluating Singapore and regional assets; and corporate-development and biomedical strategy teams.

Data sources

Singapore Ministry of Health, the Department of Statistics, the Economic Development Board, the Singapore Tourism Board, operator filings (Raffles Medical, IHH Healthcare), and analysts including Statista, IMARC, Credence Research, and ASEAN Briefing. Every figure is cited; forward-looking numbers are labeled as eFinancialModels Base Case projections.

Pair this study with a template

This study provides the sector context; to build project-level cash flows, pair it with the Full Service Hospital Model Template, the Hospital Financial Model Template, or the Healthcare Clinic Financial Model. Browse the full healthcare financial model category.

Methodology and disclosure

eFinancialModels uses AI-assisted research and drafting tools alongside human research, source verification, and editorial review. Every claim, statistic, source, chart, and recommendation was reviewed and verified before publication. This study is for informational and strategic-planning purposes only and does not constitute investment, financial, legal, or tax advice.

Download the study (PDF) below.

You must log in to submit a review.